IL110011A - Pharmacological preparations for the treatment of schizophrenia - Google Patents

Pharmacological preparations for the treatment of schizophrenia

Info

Publication number
IL110011A
IL110011A IL11001194A IL11001194A IL110011A IL 110011 A IL110011 A IL 110011A IL 11001194 A IL11001194 A IL 11001194A IL 11001194 A IL11001194 A IL 11001194A IL 110011 A IL110011 A IL 110011A
Authority
IL
Israel
Prior art keywords
immunosuppressive agent
treatment
schizophrenia
azathioprine
prednisone
Prior art date
Application number
IL11001194A
Other languages
English (en)
Hebrew (he)
Other versions
IL110011A0 (en
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL11001194A priority Critical patent/IL110011A/en
Publication of IL110011A0 publication Critical patent/IL110011A0/xx
Priority to AU28819/95A priority patent/AU704355B2/en
Priority to EP95924223A priority patent/EP0772442B1/fr
Priority to BR9508021-0A priority patent/BR9508021A/pt
Priority to PCT/EP1995/002289 priority patent/WO1995034306A1/fr
Priority to CA002192822A priority patent/CA2192822C/fr
Priority to JP8501635A priority patent/JPH10501257A/ja
Priority to DE69526584T priority patent/DE69526584T2/de
Priority to US08/750,169 priority patent/US5912250A/en
Priority to ES95924223T priority patent/ES2176331T3/es
Priority to AT95924223T priority patent/ATE216891T1/de
Publication of IL110011A publication Critical patent/IL110011A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11001194A 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia IL110011A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia
AT95924223T ATE216891T1 (de) 1994-06-13 1995-06-13 Verwendung von immunosuppressiva zur behandlung der schizophrenie
PCT/EP1995/002289 WO1995034306A1 (fr) 1994-06-13 1995-06-13 Utilisation d'agents immunosuppresseurs dans le traitement de la schizophrenie
EP95924223A EP0772442B1 (fr) 1994-06-13 1995-06-13 Utilisation d'agents immunosuppresseurs dans le traitement de la schizophrenie
BR9508021-0A BR9508021A (pt) 1994-06-13 1995-06-13 Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
AU28819/95A AU704355B2 (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia
CA002192822A CA2192822C (fr) 1994-06-13 1995-06-13 Utilisation d'agents immunosuppresseurs dans le traitement de la schizophrenie
JP8501635A JPH10501257A (ja) 1994-06-13 1995-06-13 精神分裂病の処置のための免疫抑制剤の使用
DE69526584T DE69526584T2 (de) 1994-06-13 1995-06-13 Verwendung von immunosuppressiva zur behandlung der schizophrenie
US08/750,169 US5912250A (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia
ES95924223T ES2176331T3 (es) 1994-06-13 1995-06-13 Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia

Publications (2)

Publication Number Publication Date
IL110011A0 IL110011A0 (en) 1994-10-07
IL110011A true IL110011A (en) 2004-09-27

Family

ID=11066236

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia

Country Status (11)

Country Link
US (1) US5912250A (fr)
EP (1) EP0772442B1 (fr)
JP (1) JPH10501257A (fr)
AT (1) ATE216891T1 (fr)
AU (1) AU704355B2 (fr)
BR (1) BR9508021A (fr)
CA (1) CA2192822C (fr)
DE (1) DE69526584T2 (fr)
ES (1) ES2176331T3 (fr)
IL (1) IL110011A (fr)
WO (1) WO1995034306A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
WO1999020273A1 (fr) * 1997-10-17 1999-04-29 The Rockefeller University Traitement de la schizophrenie par utilisation d'un inhibiteur de la dephosphorylation de la darpp-32
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US7112566B1 (en) * 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
EP1535616B1 (fr) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Medicament destine au syndrome de la dysfonction d'integration
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
US20100112600A1 (en) * 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions

Also Published As

Publication number Publication date
AU2881995A (en) 1996-01-05
JPH10501257A (ja) 1998-02-03
DE69526584T2 (de) 2002-11-14
EP0772442A1 (fr) 1997-05-14
ATE216891T1 (de) 2002-05-15
ES2176331T3 (es) 2002-12-01
EP0772442B1 (fr) 2002-05-02
CA2192822C (fr) 2007-04-03
BR9508021A (pt) 2004-04-20
WO1995034306A1 (fr) 1995-12-21
IL110011A0 (en) 1994-10-07
AU704355B2 (en) 1999-04-22
CA2192822A1 (fr) 1995-12-21
US5912250A (en) 1999-06-15
DE69526584D1 (de) 2002-06-06

Similar Documents

Publication Publication Date Title
Melzer et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society
Tormoehlen et al. Thymoma, myasthenia gravis, and other paraneoplastic syndromes
Vasquez Sirolimus: a new agent for prevention of renal allograft rejection
Min et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial
Mendenopoulos et al. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation
CA3131790A1 (fr) Proteine de fusion taci-fc et son utilisation
ES2965454T3 (es) Protocolo mejorado para el tratamiento de la nefritis lúpica
EP0772442B1 (fr) Utilisation d'agents immunosuppresseurs dans le traitement de la schizophrenie
US20250302858A1 (en) Use of cladribine for treating autoimmune neuromuscular disease
Rabben et al. Interindividual differences in the analgesic response to ketamine in chronic orofacial pain
Jalenques et al. Weight gain as a predictor of long term clozapine efficacy
KR20230050363A (ko) 질환의 치료에 있어서 btk 저해제의 용도
Karanikolas et al. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis.
Miranda et al. A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis
KR102893744B1 (ko) 피리메타민을 유효성분으로 포함하는 류마티스 관절염의 치료 또는 예방용 약학 조성물
US12023315B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
JP2022523018A5 (fr)
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
Ponticelli et al. The pharmacology of old and new agents for specific therapy of primary glomerular diseases
WO2020014072A1 (fr) Association pharmaceutique de néostigmine pour le traitement de la myasthénie grave
McCune et al. Immunosuppressive drug therapy for rheumatic disease
CN108478581A (zh) 防治运动病、梅尼埃病的药物及托伐普坦的医药用途
HK40106667A (en) Use of cladribine for treating autoimmune neuromuscular disease
Arnaud et al. Treatments
El-Reshaid et al. Long-term maintenance therapy with Cyclosporine A in adults with generalized pustular psoriasis.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees